After an $80M Series D raise, DalCor takes another shot at a PhIII myocardial infarction trial

Ayisha Sharma

News Reporter

DalCor Pharmaceuticals has regrouped from past setbacks to complete an $80 million Series D round to advance its cholesteryl ester transfer protein (CETP) inhibitor, dalcetrapib …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After an $80M Series D raise, DalCor takes another shot at a PhIII myocardial infarction trial

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Af­ter an $80M Se­ries D raise, Dal­Cor takes an­oth­er shot at a PhI­II my­ocar­dial in­farc­tion tri­al

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

After an $80M Series D raise, DalCor takes another shot at a PhIII myocardial infarction trial

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?